Skip to main content
Premium Trial:

Request an Annual Quote

Corixa To Acquire All Shares of GenQuest

Premium

SEATTLE--Corixa, a development-stage biotechnology company founded here in 1994, announced that it will purchase the privately held, oncology-based functional genomics company GenQuest for $11.8 million--$4.5 million in cash. Corixa currently holds approximately 17 percent of the company's outstanding capital stock. GenQuest will consolidate its operations here and be fully integrated into Corixa. The combined entity will have approximately 100 scientific employees dedicated to discovery and early development of vaccines.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.